[1]
|
于丽娟. PET/CT诊断学. 北京: 人民卫生出版社, 2009: 23.
|
[2]
|
Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med, 1995, 36(9): 1595-1601. |
[3]
|
Soloviev D, Fini A, Chierichetti F, et al. PET imaging with11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging, 2008, 35(5): 942-949. doi: 10.1007/s00259-007-0662-4 |
[4]
|
Yun M, Bang SH, Kim JW, et al. The importance of acetyl coenzyme A synthetase for11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med, 2009, 50(8): 1222-1228. doi: 10.2967/jnumed.109.062703 |
[5]
|
Song WS, Nielson BR, Banks KP, et al. Normal organ standard uptake values in carbon-11 acetate PET imaging. Nucl Med Commun, 2009, 30(6): 462-465. doi: 10.1097/MNM.0b013e32832aa7ce |
[6]
|
霍力, 周前, 吴战宏, 等. 11C-乙酸盐PET显像在肾脏肿瘤诊断中的作用. 中华核医学杂志, 2006, 26(4): 205-208.
|
[7]
|
Ponde DE, Dence CS, Oyama N, et al. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging—in vivo evaluation of18F-fluoroacetate versus11C-acetate. J Nucl Med, 2007, 48(3): 420-428. |
[8]
|
Nanni C, Castellucci P, Farsad M, et al. 11C/18F-choline PET or11C/18F-acetate PET in prostate cancer: may a choice be recommended. Eur J Nucl Med Mol Imaging, 2007, 34(10): 1704-1705. doi: 10.1007/s00259-007-0491-5 |
[9]
|
Jambor I, Borra R, Kemppainen J, et al. Functional imaging of localized prostate cancer aggressiveness using11C-acetate PET/CT and1H-MR spectroscopy. J Nucl Med, 2010, 51(11): 1676-1683. doi: 10.2967/jnumed.110.078667 |
[10]
|
Froehner M, Beuthien-Baumann B, Wirth MP. 11C-acetate positron emission tomography for occult prostate cancer. Urol Oncol, 2006, 24(5): 410-411. doi: 10.1016/j.urolonc.2005.10.003 |
[11]
|
Schiepers C, Hoh CK, Nuyts J, et al. 1-11C-acetate kinetics of prostate cancer. J Nucl Med, 2008, 49(2): 206-215. doi: 10.2967/jnumed.107.044453 |
[12]
|
Albrecht S, Buchegger F, Soloviev D, et al. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging, 2007, 34(2): 185-196. doi: 10.1007/s00259-006-0163-x |
[13]
|
Seppa la J, Sepp. a. nen M, Arponen E, et al. Carbon-11 acetate PET/ CT based dose escalated IMRT in prostate cancer. Radiother Oncol, 2009, 93(2): 234-240. doi: 10.1016/j.radonc.2009.08.010 |
[14]
|
Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with11C-acetate and18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging, 2003, 30(4): 607-611. doi: 10.1007/s00259-002-1104-y |
[15]
|
Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of[11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging, 2002, 29(11): 1492-1495. doi: 10.1007/s00259-002-0885-3 |
[16]
|
Ho CL, Yu SC, Yeung DW, et al. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med, 2003, 44(2): 213-221. |
[17]
|
Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F]fluoro-D-glucose, [1-11C]-acetate and[N-methyl-11C]-choline. Q J Nucl Med Mol Imaging, 2009, 53(2): 144-156. |
[18]
|
Park JW, Kim JH, Kim SK, et al. A prospective evaluation of18FFDG and11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med, 2008, 49(12): 1912-1921. doi: 10.2967/jnumed.108.055087 |
[19]
|
Magini G, Farsad M, Frigerio M, et al. C-11 acetate does not enhance usefulness of F-18FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med, 2009, 34(10): 659-665. doi: 10.1097/RLU.0b013e3181b53488 |
[20]
|
Lhommel R, Annet L, Bol A, et al. PET scan with11C-acetate for the imaging of liver masses: report of a false positive case. Eur J Nucl Med Mol Imaging, 2005, 32(5): 629. doi: 10.1007/s00259-004-1698-3 |
[21]
|
Huo L, Wu Z, Zhuang H, et al. Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin Nucl Med, 2009, 34(12): 874-877. doi: 10.1097/RLU.0b013e3181bed06e |
[22]
|
Oyama N, Okazawa H, Kusukawa N, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging, 2009, 36(3): 422-427. doi: 10.1007/s00259-008-0981-0 |
[23]
|
Ho CL, Cheng TKC, Yeung DWC, et a1. 11C-acetate PET imaging in thedifferentiationofrenalangiomyolipomaandrenalcell carcinoma. J Nucl Med, 2005, 46(5): 103. |
[24]
|
Shriki J, Murthy V, Brown J, et al. Renal oncocytoma on 1-11C acetate positron emission tomography: Case report and literature review. Mol Imaging Biol, 2006, 8(4): 208-211. doi: 10.1007/s11307-006-0040-9 |
[25]
|
Liang CY, Liu X, Zhang JM, et al. Biodistribution and positron emission tomography imaging of11C-acetate in murine model of lung carcinoma. Zhonghua Yi Xue Za Zhi, 2008, 88(11): 778-780. |
[26]
|
Nomori H, Shibata H, Uno K, et al. 11C-Acetate can be used in place of18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for welldifferentiated adenocarcinoma. J Thorac Oncol, 2008, 3(12): 1427-1432. doi: 10.1097/JTO.0b013e31818ddfdc |
[27]
|
Kaji M, Nomori H, Watanabe K, et al. 11C-acetate and18F-fluorodeoxyglucose positron emission tomography of pulmonary adenocarcinoma. Ann Thorac Surg, 2007, 83(1): 312-314. doi: 10.1016/j.athoracsur.2006.05.085 |
[28]
|
Nomori H, Kosaka N, Watanabe K, et al. 11C-acetate positron emission tomography imaging for lung adenocarcinoma 1 to 3 cm in size with ground-glass opacity images on computed tomography. Ann Thorac Surg, 2005, 80(6): 2020-2025. doi: 10.1016/j.athoracsur.2005.06.003 |
[29]
|
Shibata H, Nomori H, Uno K et al. 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness. Ann Nucl Med, 2009, 23(7): 609-616. doi: 10.1007/s12149-009-0278-9 |
[30]
|
Sun A, So rensen J, Karlsson M, et al. 1-[11C]-acetate PET imaging in head and neck cancer—a comparison with18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging, 2007, 34(5): 651-657. doi: 10.1007/s00259-006-0298-9 |
[31]
|
Yamamoto Y, Nishiyama Y, Kimura N, et al. 11C-acetate PET in the evaluation of brain glioma: comparison with11C-methionine and18FFDG-PET. Mol Imaging Biol, 2008, 10(5): 281-287. doi: 10.1007/s11307-008-0152-5 |
[32]
|
Tsuchida T, Takeuchi H, Okazawa H, et al. Grading of brain glioma with 1-11C-acetate PET: comparison with18F-FDG PET. Nucl Med Biol, 2008, 35(2): 171-176. doi: 10.1016/j.nucmedbio.2007.11.004 |
[33]
|
Wang HC, Zhao J, Zuo CT, et al. Encephalitis depicted by a combination of C-11 acetate and F-18 FDG PET/CT. Clin Nucl Med, 2009, 34(12): 952-954. doi: 10.1097/RLU.0b013e3181bed0c1 |
[34]
|
Yeh SH, Liu RS, Wu LC, et al. 11C-acetate clearance in nasopharyngeal carcinoma. Nucl Med Commun, 1999, 20(2): 131-134. doi: 10.1097/00006231-199902000-00004 |
[35]
|
Ohtsuka T, Nomori H, Watanabe K, et al. Positive imaging of thymoma by11C-acetate positron emission tomography. Ann Thorac Surg, 2006, 81(3): 1132-1134. doi: 10.1016/j.athoracsur.2005.01.024 |
[36]
|
Shibata H, Nomor H, Uno K, et al. 18F-Fluorodeoxyglucose and11C-acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma. Cancer, 2009, 115(11): 2531-2538. doi: 10.1002/cncr.24278 |
[37]
|
Shreve PD, Gross MD. Imaging of the pancreas and related diseases with PET carbon-11-acetate. J Nucl Med, 1997, 38(8): 1305-1310. |
[38]
|
Lee SM, Kim TS, Lee JW, et al. Incidental finding of an11C-acetate PET-positive multiple myeloma. Ann Nucl Med, 2010, 24(1): 41-44. doi: 10.1007/s12149-009-0325-6 |